Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Accumulated Expenses (2016 - 2022)

Historic Accumulated Expenses for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $8.0 million.

  • Avadel Pharmaceuticals' Accumulated Expenses fell 884.64% to $8.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $8.0 million, marking a year-over-year decrease of 884.64%. This contributed to the annual value of $7.2 million for FY2021, which is 999.85% up from last year.
  • As of Q3 2022, Avadel Pharmaceuticals' Accumulated Expenses stood at $8.0 million, which was down 884.64% from $9.7 million recorded in Q2 2022.
  • Over the past 5 years, Avadel Pharmaceuticals' Accumulated Expenses peaked at $45.9 million during Q1 2018, and registered a low of $4.3 million during Q1 2021.
  • For the 5-year period, Avadel Pharmaceuticals' Accumulated Expenses averaged around $15.0 million, with its median value being $14.9 million (2020).
  • Per our database at Business Quant, Avadel Pharmaceuticals' Accumulated Expenses skyrocketed by 13047.75% in 2018 and then tumbled by 7107.96% in 2021.
  • Avadel Pharmaceuticals' Accumulated Expenses (Quarter) stood at $21.7 million in 2018, then decreased by 8.69% to $19.8 million in 2019, then crashed by 67.18% to $6.5 million in 2020, then rose by 10.0% to $7.2 million in 2021, then rose by 11.38% to $8.0 million in 2022.
  • Its Accumulated Expenses was $8.0 million in Q3 2022, compared to $9.7 million in Q2 2022 and $9.4 million in Q1 2022.